Advertisement

Topics

Resistant Hypertension Pipeline Insight, 2017 [Report Updated: 31072017] Prices from USD $1250

05:36 EDT 7 Aug 2017 | BioPortfolio Reports

DelveInsight's, Resistant HypertensionPipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Resistant Hypertension. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of Resistant Hypertension by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsights team of industry experts.

Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the report

The report provides a snapshot of the pipeline development for the Resistant Hypertension
The report covers pipeline activity across the complete product development cycle i.e. clinical, preclinical and discovery stages for the Resistant Hypertension
The report provides pipeline product profiles which includes product description, developmental activities, licensors collaborators and chemical information
Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Resistant Hypertension
The report also covers the dormant and discontinued pipeline projects related to the Resistant Hypertension

Reasons to Buy

Establish comprehensive understanding of the pipeline activity across this Resistant Hypertension to formulate effective RD strategies
Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Resistant Hypertension therapeutics
Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Original Article: Resistant Hypertension Pipeline Insight, 2017 [Report Updated: 31072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Resistant Hypertension Pipeline Insight, 2017 [Report Updated: 31072017] Prices from USD $1250"

Quick Search
Advertisement
 

Relevant Topics

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...